PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Full Results from Phase 1 Clinical Trial of PB2452 in New England Journal of Medicine

Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session

PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects

Results support continued development of PB2452 as ticagrelor reversal agent

MALVERN, Penn. and SAN DIEGO, March 17, 2019 (GLOBE NEWSWIRE) --  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that... More